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a b s t r a c t
Marginal zone (MZ) B cells generate T-independent antibody responses to pathogens before T-
dependent antibodies arise in germinal centers. They have been identiﬁed in cynomolgus monkeys
and monitored during acute SIV infection, yet have not been well-studied in rhesus macaques. Here we
characterized rhesus macaque MZ B cells, present in secondary lymphoid tissue but not peripheral blood,
as CD19þ , CD20þ , CD21hi, IgMþ , CD22þ , CD38þ , BTLAþ , CD40þ , CCR6þ and BCL-2þ . Compared to
healthy macaques, SHIVSF162P4-infected animals showed decreased total B cells and MZ B cells and
increased MZ B cell Ki-67 expression early in chronic infection. These changes persisted in late chronic
infection, despite viremia reductions to low or undetectable levels. Expression levels of additional
phenotypic markers and RNA PCR array analyses were in concert with continued low-level activation
and diminished function of MZ B cells. We conclude that MZ B-cell dysregulation and dysfunction
associated with SIV/HIV infection are not readily reversible.
Published by Elsevier Inc.
Introduction
HIV infection profoundly affects B-cell functions leading to
dysregulation. Compared to the partial reversal of CD4þ T-cell
loss in the periphery and gut mucosa by ART therapy, B-cell
dysregulation is not fully reversed (D’Orsogna et al., 2007; Moir
and Fauci, 2009; Regidor et al., 2011), although early ART may help
prevent it (Moir et al., 2010). B-cell dysregulation occurs early after
HIV and SIV infection, usually before CD4þ T-cells decline, and
strikingly manifests itself by skewing memory populations
(Chagnon-Choquet et al., 2014; Kuhrt et al., 2010; Titanji et al.,
2010, 2014). Additional broader effects of HIV infection on B-cells
have been recently reviewed (Moir and Fauci, 2009).
Little is known about the effect of chronic HIV/SHIV infection on
marginal zone (MZ) B-cells. MZ B-cells are a subset of B-cells found in
secondary lymphoid organs that are responsible for an early antibody
response to blood-borne pathogens (Lopes-Carvalho et al., 2005).
Thus, they bridge innate and later occurring adaptive responses
(Cerutti et al., 2013). MZ B cells may play important roles in HIV/SIV
infection. They express high levels of complement receptor 2 (CR2/
CD21) and thus can capture immune complexes efﬁciently. In addi-
tion the engagement of CD21 lowers the B-cell activation threshold
(Carroll and Isenman, 2012). Cytokine and antibody production may
also contribute to viremia control. In fact, maintenance of IL-10 and
lymphotoxin-α levels in peripheral blood MZ-like B cells was asso-
ciated with control of HIV-1 disease progression (Chagnon-Choquet et
al., 2014). On the other hand, complement receptor 2 expression
might contribute to establishment of an extracellular HIV reservoir in
lymph nodes by capturing and maintaining HIV trapped in the form
of immune complexes (Ho et al., 2007). HIV trapped on B-cells has
been shown to remain infectious in an in-vitro infectivity assay (Moir
et al., 2000). Therefore it is important to further elucidate the role and
contributions of marginal zone B-cells in HIV/SHIV pathogenesis.
Here we have extensively phenotyped MZ B cells in rhesus
macaques, and have examined this B cell subpopulation before and
after infectionwith SHIVSF162P4 in order to gain insight into its potential
contribution to infection outcome. It has been reported that cynomol-
gus monkey MZ B cells are dysregulated and diminished in function
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during early SIV infection (Peruchon et al., 2009). The SHIV-infected
macaques exhibited control of viremia to low or undetectable levels
over the course of disease progression, providing an opportunity to
determine whether MZ B cell dysregulation is persistent or reversed
with viremia control.
Results
Phenotype of rhesus macaque MZ B cells
MZ B cells of cynomolgus monkeys were previously reported to be
CD21hi, CD27 /þ (Vugmeyster et al., 2004). We conﬁrmed the
presence of the CD21hi phenotype in LN and spleen of rhesus
macaques, but not in PBMC (Fig. 2). The average mean ﬂuorescent
intensity (MFI) for CD21 on naïve CD21þ splenic B-cells was 5785
whereas for MZ B-cells it was 39620 (6.8-fold higher). We conﬁrmed
low-level expression of CD27 onMZ B cells, but would classify them as
CD27 /dim (Fig. 2A) based on a comparison of CD27 MFIs between
MZ-B-cells (MFI of 410), resting (CD21þCD27þ) B-cells (MFI of 1387)
and naïve (CD21þCD27) B-cells (MFI of 183).
We further phenotyped the cells and documented expression of
additional B-cell markers (Table 2). The most highly and consistently
expressed surface markers aside from CD19, CD20, and CD21, were
IgM, CD22, BTLA, CD40, CD38, CCR6 and BCL-2. Over 90% of all
CD21hi B-cells were positive for these markers (Table 2). Over 80% of
CD21hi B-cells were also positive for IgD and HLA-DR (Table 2). Based
on these data, we characterize rhesus macaque MZ B-cells as CD19þ ,
CD20þ , CD21hi, IgMþ , CD22þ , CD38þ , BTLAþ , CD40þ , CCR6þ and
BCL-2þ with some variation in expression of IgD and HLA-DR.
Inﬂuence of SHIV viremia on MZ B cells
Initially we examined MZ B cells in LNs of macaques early in
chronic infection. The infected previously vaccinated and control
animals showed no differences in viral loads (Fig. 1) and were
therefore treated as a single group (see Materials and methods
section). Comparing samples obtained prior to study initiation with
those obtained 8 weeks post-infection we observed a decline in total
B cells together with a signiﬁcant drop in MZ B-cells (p¼0.023 and
0.021, respectively; Fig. 3A and B). Correlation analysis indicated a
weak trend in the decline in LN MZ B cells with plasma viral load
(r¼0.43; Fig. 3C). We also observed signiﬁcantly increased expression
of Ki-67 8 weeks post-infection compared to pre samples (po0.0001;
Fig. 3D), directly correlated with viremia (r¼0.66; Fig. 3E). Surface
expression of three additional markers was examined. LN MZ B-cells
post-infection downregulated CD22 (Siglec-2) expression (po0.0001,
Fig. 3F), upregulated IgD (po0.0001, Fig. 3G), and expressed high
levels of CD38, a marker highly expressed on human plasma cells,
although the proportion of positive cells was slightly downregulated
post-infection (p¼0.028, Fig. 3H). CD38 expression by MFI was
signiﬁcantly higher on MZ B-cells (CD21hi) compared to naïve
(CD21þCD27) (po0.01) or resting (CD21þCD27þ) B-cells
(po0.0001) (mean MFI values of 5699, 5003, and 3088, respectively).
However the MFI of CD38 pre and post-infection was unchanged
(data not shown).
We next examined macaque B cells late in the chronic phase of
SHIVSF162P4 infection. The percentages of B-cells in circulation
(PBMC) were not different between infected and uninfected
macaques (Fig. 4A). However as reported for HIV infected humans
(Chagnon-Choquet et al., 2014; Titanji et al., 2014) we saw
signiﬁcant skewing of memory B-cell subsets between healthy
and chronically infected animals (Fig. 4B). In infected animals,
naïve B cells were decreased and activated memory B cells
increased compared to healthy animals (p¼0.0081 for each). In
contrast, a surprising decline in total splenic B cells in SHIV-
infected animals was seen (p¼0.048, Fig. 4C), in concert with the
decline seen early in chronic phase in LN (Fig. 3A). Similarly, a drop
in splenic MZ B cells was observed (p¼0.028, Fig. 4D). We could
not determine if as with the LN cells, this decline was correlated
Table 1
Antibody clones and colors used for ﬂow cytometry.
Antigen Color Clone Host species Isotype Supplier
CD2 Qdot605 S5.5 Mouse IgG2a Invitrogen
CD3 BV605 SP34-2 Mouse IgG1,λ BD Bioscience
CD14 Qdot605/Qdot800 Tu14 Mouse IgG2a Invitrogen
CD19 PeCy5 J3-119 Mouse IgG1 Beckman Coulter
CD20 eF650NC 2H7 Mouse IgG2b,κ eBioscience
CD21 PeCy7 B-ly4 Mouse IgG1,κ BD Bioscience
CD22 Pe RFB-4 Mouse IgG1 Invitrogen
CD23 APC M-L233 Mouse IgG1,κ BD Bioscience
CD27 PerCP-eF710 O323 Mouse IgG1,κ eBioscience
CD38 FITC AT-1 Mouse IgG1 Stem Cell Technologies
CD40 Ax700 5C3 Mouse IgG1,κ BD Bioscience
CD69 APC-Cy7 FN50 Mouse IgG1,κ Biolegend
CD86 APC IT2.2 Mouse IgG2b,κ Biolegend
CD95 FITC DX2 Mouse IgG1,κ BD Bioscience
CD184 (CXCR4) BV421 12G5 Mouse IgG2a,κ Biolegend
CD196 (CCR6) Pe 11A9 Mouse IgG1,κ BD Bioscience
CDw199 (CCR9) FITC 112509 Mouse IgG2a R&D Systems
CD257 (BAFF/BlyS) Pe T7-241 Mouse IgG1,κ Biolegend
CD272 (BTLA) Pe J168-540 Mouse IgG1,κ BD Bioscience
α4β7 APC A4B7 Rhesus recombinant IgG1 NHP Reagent Resource
IgD Texas Reda Polyclonal Goat NA Southern Biotech
IgM APC/BV421 G20-127 Mouse IgG1,κ BD Bioscience
activated Caspase 3 FITC C92-605 Rabbit IgG BD Bioscience
Ki-67 Ax700 B56 Mouse IgG1,κ BD Bioscience
BCL-2 Pe 100 Mouse IgG1 Invitrogen
BCL-6 Pe IG191E/A8 Mouse IgG1 Biolegend
IRF-4 eFluor660/FITC 3E4 Rat IgG1,κ eBioscience
AID FITC Polyclonal Rabbit NA Bioss
HLA-DR Qdot800 Tu36 Mouse IgG2b Invitrogen
Viability Dye Aqua NA NA NA Invitrogen
a Green laser (532 mm) or yellow–green laser (561 nm) required.
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with viremia, as viral loads at the time of necropsy were mostly
undetectable (Fig. 1). Finally, the CD21þCD27þ resting memory B-
cell sub-population in spleen cells of infected macaques was
increased (p¼0.028, Fig. 4E).
MZ B cell expression of co-stimulatory and activation markers in
infected and uninfected macaques
We postulated that the declines in total B cells and MZ B cells in
infected macaques might be driven by chronic activation. There-
fore, we investigated co-stimulatory markers and markers of cell
activation on splenic MZ B-cells. Expression of the co-stimulatory
molecule CD86 (B7-2) was unaltered in splenic MZ B cells between
healthy and chronically infected animals (Fig. 5A). In contrast,
CD86 was signiﬁcantly down-regulated in naïve, resting, and
tissue-like memory B-cells of PBMC from the infected macaques
(p¼0.0040, 0.0040, and 0.028, respectively), with a similar ten-
dency in activated memory (CD21CD27þ) cells (Fig. 5B). No
difference was seen in expression levels of CD40 between healthy
and chronically infected macaques. In both groups, over 95% of
splenic MZ B-cells were positive (data not shown). On the other
hand, CD69 expression was elevated in chronically infected ani-
mals compared to healthy (Fig. 5C) indicating low level activation,
although the difference did not reach statistical signiﬁcance.
Splenic MZ B-cells from chronically infected animals similarly
expressed higher levels of the proliferation marker Ki-67 with
marginal signiﬁcance (p¼0.048, Fig. 5D) compared to the healthy
controls. Other markers involved in control of B-cell activation and
homeostasis such as CD272 (BTLA) and membrane bound Baff/BlyS
(CD257) were expressed at slightly lower levels in the infected
animals or remained unchanged (Fig. 5E and F). No difference in
MHC-class II expression (HLA-DR) between healthy and chroni-
cally infected animals was observed (Fig. 5G).
In view of the higher Ki-67 expression on MZ B cells of infected
macaques together with the suggestion of low-level activation, we
investigated expression of caspase 3. In T-cells Caspase 3, an
execution Caspase of the apoptosis pathway (MacKenzie and
Clark, 2012), can be upregulated during activation (McComb et
al., 2010). Further, HIV infection induces activation of Caspase 3 in
human CD4 T-cells (Cicala et al., 2000). Whether similar up-
regulation occurs in B cells is not known. Here, the expression of
active Caspase-3 was slightly higher on MZ B cells of infected
compared to uninfected macaques (Fig. 6A). In line with this result,
expression of survival factor BCL-2 tended to be lower in SHIV
infected animals (Fig. 6B). It is known that multiple caspases are
able to cleave BCL-2 (Garcia-Saez, 2012; Guerrero et al., 2013).
Although no signiﬁcant changes were seen in splenic MZ B cells,
we noted a signiﬁcant drop in CD40þBCL-2þ expression in both
activated and tissue like (CD21CD27) memory B-cell subsets in
spleen and PBMC of infected macaques (Fig. 6C and D).
The drop in MZ B-cells post infection (Fig. 4D) was accompanied by
a drop in IgD surface expression on splenic MZ B cells of infected
macaques (p¼0.028, Fig. 7A), together with a marginal increase in
Fig. 1. Plasma viral loads in macaques at the time of sampling. LN were
collected 8 weeks post-SHIVSF162P4 infection from 13 previously immunized and
5 control macaques. Spleens and PBMC were collected from 8 SHIVSF162P4-infected
macaques at necropsy, (wk26–28 post challenge). Viremia for each macaque at the
time of sample collection is shown with means and Standard error of the mean
(SEM). The sensitivity of viral detection was 50 RNA copies/ml plasma.
Fig. 2. Identiﬁcation of MZ B-cells in rhesus macaque tissues. Representative ﬂow cytometry staining of MZ B cells and memory B-cell sub-populations in spleen (A), LN
(B) and PBMC (C). The MZ B-cell population stands out in spleen and LN as CD21hi.
Table 2
Characterization of marginal zone B-cells.
Marker % Mean positive cells ranked highest to lowest
CD19 100a
CD20 100a
CD21 100a
CD38 495
CD272 495
CD40 495
CCR6 495
CD22 490
IgM 490
BCL-2 490
IgD 480
HLA-DR 480
CD95 59
CD86 35
CD257 24
CD23 10
CXCR4 o10
CCR9 o2
α4β7 o2
Ki-67 o1
CD69 o1
BCL-6 o0.5
active Caspase-3 o0.1
a Essential marginal zone B-cell gating markers. MZ B-cells were evaluated in
LN and spleen from healthy animals.
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IgDIgMþ MZ B-cells (p¼0.048, Fig. 7B). These ﬁndings corroborate
the low-level activation and elevated expression of CD69 and Ki-67 in
infected animals (Fig. 5C and D). Finally, we examined whether these
changes were associated with altered homing properties of splenic MZ
B-cells. The cells from chronically infected animals downregulated
CCR6 expression (p¼0.028, Fig. 7C). On the other hand, expression of
CXCR4 and the mucosal homing marker α4β7 (Fig. 7D and E) on MZ B
cells tended to increase in comparison to cells from healthy animals.
Differences between MZ B cells of healthy and infected macaques by
PCR array
In late chronic infection, despite control of viremia to low or
undetectable levels, low level chronic activation may have led to
persistent differences between MZ B cells of healthy and infected
animals. To further address this we sorted splenic MZ B-cells from
3 chronically infected and 3 healthy animals, isolated RNA, and
compared expression levels of innate and adaptive response genes
by Rhesus monkey speciﬁc PCR array. Using a stringent 2-fold
increase or decrease in mean as well as median gene expression,
we found substantial differences between the healthy and
chronically infected animals (Table 3). The majority of down-
regulated genes encoded cytokines and chemokines. Overall MZ
B cells from infected animals were more limited in their capacity
for producing cytokine/chemokines compared to healthy animals.
On the other hand the majority of genes that were upregulated in
infected compared to uninfected macaques were transcription
factors including IRF-1, FoxP3, T-box 21 and signaling molecules
NLRP3, STAT1 (Table 3). Interestingly chemokine receptors CXCR3
and CCR5 were elevated in infected monkeys, indicating some
changes in homing pattern as observed for α4β7 and CXCR4. Not
only did MZ B cells from infected macaques downregulate che-
mokines and cytokines, corresponding receptors were downregu-
lated too, further indicating that the cells are limited in the ability
to respond to outside stimuli (Table 3). In line with this, down-
regulation of innate receptors TLR3 and TLR5 was also observed.
Discussion
There is good agreement on the deﬁnition of splenic MZ B cells
of mouse and human as CD21þ /hi, IgMhi, IgDlo, and CD23/lo
Fig. 3. Comparison of LN MZ B cells in healthy vs infected macaques in early chronic phase. Loss of total B-cells (A) and decrease in MZ B-cells 8 weeks post-infection
(B) in axillary LN. Correlation of decrease in MZ B cells with viral load 8 weeks post-infection (C). Increase in Ki-67 expression on MZ B cells post-infection (D); mean
difference 2.0% (95% C.I. 0.9% to 3.0%). Correlation of increase in Ki-67 expression with viral load 8 weeks post-infection (E). Comparison of CD22 (F); mean difference 13%
(95% C.I. 8% to 19%), IgD (G); mean difference 5.5% (95% C.I. 3.4% to 7.5%), and CD38 (H) expression on MZ B cells pre- and post-infection; mean difference 0.5% (95% C.I.
1.5% to 0.3%). Linear regression lines shown on (C) and (E) are to aid interpretation of the data only (no functional form is implied).
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(Martin and Kearney, 2002; Weill et al., 2009; Cerutti et al., 2013).
Additional markers have been reported, including CD1hi (Martin
and Kearney, 2002), CD1cþ and CD27þ (Weill et al., 2009; Cerutti
et al., 2013), and CD5 (Weill et al., 2009). Human MZ B cells have
also been described as CD10 (Chagnon-Choquet et al., 2014). Not
many publications have addressed MZ B-cells in non-human
primates although B cell memory subpopulations have been
examined in secondary lymphoid tissues (Das et al., 2011;
Demberg et al., 2012; Titanji et al., 2010). Vugmeyster et al.
(2004) identiﬁed CD21 as a marker of cynomolgus monkey MZ B
cells, consistent with the MZ B cell phenotype of mice and
humans. Here we conﬁrm the CD21hi phenotype of rhesus maca-
que MZ B cells (Fig. 2A). While we did not stain for CD1, CD1c,
CD10 or CD5, we conﬁrmed low expression of CD23 and high
expression of CD22 (Fig. 3F and Table 2). We observed high
expression of IgM on rhesus MZ B-cells (Table 2); the majority of
cells co-expressed IgD (data not shown). While CD27 is expressed
on human MZ B cells at relatively high levels (Weill et al., 2009;
Chagnon-Choquet et al., 2014), our data categorizing rhesus
macaque MZ B-cells as CD27 /dim are in line with Vugmeyster et
al., (2004) who described cynomolgus monkey MZ B cells as
CD27/þ , and in contrast to results of Peruchon et al. (2009)
who described cynomolgus monkey MZ B cells as CD27þ IgDþ . We
were unable to detect CD21hi B-cells in blood (data not shown),
which might be in part due to the extremely low frequency of
CD21hi compared to CD27þ IgDþ cells in Rhesus macaques. A
similar observation was also reported by Vugmeyster et al.
(2004) for cynomolgus monkeys. While Messaoudi et al. (2011)
described MZ-like cells in blood of rhesus macaques, the CD21
marker was not used. The lack of circulating CD21hi MZ B-cells
could point to a species difference between humans and non-
human primates. Overall our data with regard to the frequency of
MZ B-cells in axillary LN (16%) and spleen (17%) are in accord
with results of Peruchon et al. (2009) (LN, 22% and spleen,
17%) and higher compared to Vugmeyster et al. (2004).
We report here high level expression of CD38 on rhesus
macaque MZ B cells (Table 2, Fig. 3H), consistent with similar high
expression on mouse MZ B cells (Oliver et al., 1997; Pillai et al.,
2005). Reports on human cells have been conﬂicting, and require
further clariﬁcation. Colombo et al. (2013) reported human splenic
MZ B-cells to be CD38 while Benitez et al. (2014) by gating on
CD24 and CD38 identiﬁed a B-cell population in human spleen
characteristic of MZ B-cells that was CD38þ CD21hi. MZ B-cells
play a role in the early immune response to pathogens in a T-
independent and T-dependent fashion (Zouali and Richard, 2011).
CD38 has been shown to be important for the innate response to
Listeria infection (Lischke et al., 2013). Further, in bulk puriﬁed
mouse spleen B-cells stimulated with TLR7 agonist, anti-CD38
antibody and IL-4 led to a strong increase in production of IgM and
to a varying degree also induced IgG1 production (Tsukamoto et
al., 2009). Thus expression of CD38 on MZ B-cells as shown here
would be meaningful for mounting rapid responses triggered
through innate receptors.
CD22 was highly expressed on rhesus macaque MZ B-cells in
both spleen (data not shown) and LN (Fig. 3F), similar to the high
expression reported for mouse and human MZ B-cells (Martin and
Kearney, 2002; Colombo et al., 2013). CD22 is a negative regulator
of B-cell activation (Muller and Nitschke, 2014), and in mice B-cell
homeostasis requires CD22 and BlyS (BAFF)-BR3 signaling for
survival (Smith et al., 2010). MZ B-cells were shown to be reduced
using anti-Baff and anti-CD22 antibodies (Smith et al., 2010).
Similarly, a Baff antagonist decreased MZ B cells in cynomolgus
monkeys (Vugmeyster et al., 2006). Here we showed that over 20%
of splenic MZ B-cells were positive for membrane bound Baff/BlyS
(Fig. 5E). There was no difference in Baff expression between SHIV-
infected and healthy animals, consistent with a previous report
showing no difference in plasma Baff levels between HIV infected
children and healthy controls (Cagigi et al., 2010).
In mice MZ B-cells express high levels of MHC class II, CD80 and
CD86 (Cerutti et al., 2013). Our ﬁndings for rhesus macaque MZ B-
cells show some similarities. The majority of splenic CD21hi MZ B-
cells were positive for MHC-class II (Table 2). We did not
investigate CD80, but CD86 was moderately expressed (Fig. 5A,
Table 2). Mouse MZ B-cells express high levels of CD40 (Oliver
et al., 1997). We found high expression of CD40 on Rhesus MZ B-
cells (Table 2) consistent with the mouse data.
Fig. 4. Comparison of splenic B cells in healthy vs infected macaques in late chronic phase. No difference in total B-cell frequency in PBMC (A), but skewing of memory
B-cell populations in PBMC (B) following SHIVSF162P4 infection (infected, closed circles; uninfected, open circles). Differences in total B-cells (C), MZ B-cells (D) and resting
B-cells (E) in spleen between infected and healthy animals. Error bar¼SEM.
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Fig. 5. Differential expression of activation markers on MZ B-cells in spleen between infected and healthy animals. Expression of activation marker CD86 on splenic MZ
B-cells of infected and uninfected animals (A); and on memory B-cell populations in PBMC of infected (closed circles) and uninfected (open circles) macaques (B). Expression
of the activation marker CD69 (C) and the proliferation marker Ki-67 (D) on MZ B-cells of infected and uninfected animals. Expression of MZ B-cell bound Baff (CD257) (E),
the negative regulatory receptor BTLA (CD272) (F), and HLA-DR (G) on MZ B cells of infected and uninfected animals. Error bar¼SEM.
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The B and T lymphocyte attenuator (BTLA, CD272), a lympho-
cyte inhibitory receptor with similarities to CTLA-4 and PD-1 on T
cells (Watanabe et al., 2003) was highly expressed on CD21hi
splenic MZ B cells (Table 2, Fig. 5F). This is consistent with the high
expression of BTLA on unstimulated IgDþCD27þ B-cells in the
blood of healthy volunteers (Thibult et al., 2013). These cells are
considered to be MZ-like B-cells (Messaoudi et al., 2011; Peruchon
et al., 2009). In humans, B-cell activation via TLR9 (CPG-ODN DNA)
Fig. 6. Comparison of apoptosis and survival marker expression by splenic MZ B-cells between healthy and SHIV infected animals. Trends for elevation of active
Caspase 3 expression (A) and decreased BCL-2 expression (B) on MZ B-cells from infected animals. Changes in co-expression of BCL-2 and CD40 in memory B-cell sub-
populations of spleen (C) and PBMC (D) between infected (closed circles) and healthy (open circles) animals were observed. Error bar¼SEM.
Fig. 7. Changes in isotype and homing marker expression on splenic MZ B-cells between infected and healthy animals. MZ B-cells from infected animals down
regulated the expression of IgD (A) while the frequency of IgDIgMþ MZ B-cells increased (B). Homing receptor CCR6 expression was signiﬁcantly lower (C), while CXCR4
(D) and α4β7 (E) expression levels were elevated on MZ B-cells of infected animals. Error bar¼SEM.
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induced and sustained expression of BTLA (Thibult et al., 2013).
This observation is of interest as TLR9 signaling drives human
transitional (CD24hi) B-cells towards the MZ B-cell pathway
(Guerrier et al., 2012). The role of BTLA receptor on MZ B-cells is
unclear, but it might help regulate T-cell independent immuno-
globulin production (Thibult et al., 2013).
Literature on expression of homing markers on MZ B-cells is
somewhat scarce. However CCR6 expression in human spleen
samples was speciﬁcally seen in mantle and marginal zones but
not in follicles (Rodig et al., 2002), suggesting that MZ B-cells
might be CCR6 positive. Further, 84% of marginal zone/MALT
lymphomas tested positive for the expression of CCR6 in contrast
to no follicular lymphomas (Rodig et al., 2002). Our ﬂow data
conﬁrm that CCR6 is highly expressed on Rhesus MZ B-cells
(Table 2, Fig. 7C). Low level expression of CXCR4 and α4β7 was
also observed (Fig. 7D and E).
Having extensively phenotyped rhesus macaque MZ B cells, we
compared features of this B cell population in early and late chronic
SHIVSF162P4 infection to uninfected animals. Cynomolgus monkeys
display a decline in MZ B cells within the ﬁrst 4 weeks of SIV infection
(Peruchon et al., 2009). Our LN data during early chronic phase, wk8
post-infection, showed a similar decrease, which persisted in splenic
MZ B cells in late chronic phase. This overall decline might be
attributable to differentiation of these cells into antibody secreting
cells which lose the CD21hi phenotype as described by Zouali and
Richard (Zouali and Richard, 2011). We conﬁrmed in preliminary
experiments using ex-vivo TLR ligand stimulation of rhesus macaque
splenic B cells that CD21hi cells are lost 3 days post-stimulation
(unpublished). Thus the decline in MZ B-cells might be attributable to
cell differentiation into other phenotypes.
Not only are MZ B cells reduced in LN and spleen in early (Fig. 4B)
and chronic SHIV infection (Fig. 4D), but also total B-cells are reduced
(Fig. 3A; Fig. 4C). We considered that dysregulation of CD40L,
provided by CD4 T cells, might have contributed to these reductions.
In the absence of CD40L, B-cells might become anergic and undergo
apoptosis, as it is known that activation by CD40 cross-linking induces
strong proliferative responses in MZ B cells (Oliver et al., 1997).
However, CD40L can also be expressed on DC during viral infections,
Table 3
Differences in RNA expression of SHIV-infected versus healthy rhesus macaques by PCR array analysis.
UniGene Fold Fold Fold Fold
Decrease Decrease Increase Increase
(Mean) (Median) (Mean) (Median)
Cytokines/chemokines
Mmu.3376 IL-6 . 2.1 . .
Mmu.3491 CCL2 7.1 22.0 . .
Mmu.3665 CSF2 9.0 36.0 . .
Mmu.15664 IFN-b1 4.4 11.0 . .
Mmu.3374 IL-10 6.3 8.9 . .
Mmu.3675 IL-13 12.4 27.7 . .
Mmu.3414 IL-15 2.3 2.3 . .
Mmu.14785 IL-17A 7.9 22.2 . .
Mmu.3361 IL-1a 11.1 25.5 . .
Mmu.3415 IL-2 5.4 16.8 . .
Mmu.18854 IL-23A 2.7 2.7 . .
Mmu.3375 IL-4 7.3 23.3 . .
Mmu.3363 IL-8 7.0 16.1 . .
Mmu.3698 CCL5 . . 2.1 .
Cytokine/chemokine receptors
Mmu.12735 IL-1R1 5.0 7.7 . .
Mmu.14927 CCR4 4.0 10.9 . .
XM_001084047 CCR8 6.0 12.7 . .
Mmu.8534 CXCR3 . . 2.3 .
Mmu.3440 CCR5 . . 2.2 2.2
Complement components
Mmu.3133 C3 2.8 2.8 . .
Mmu.3027 LBP 11.2 37.8 . .
Mmu.3409 MBL2 18.2 59.3 . .
PRR/inﬂammasome
Mmu.12334 NLRP3 . . . 2.2
Mmu.3813 TLR3 2.3 4.2 . .
Mmu.3815 TLR5 3.9 6.6 . .
Signaling/transcription
Mmu.13224 STAT4 . 3.0 . .
Mmu.13939 T-box 21 . . . 2.2
Mmu.11578 IRF-1 . . 3.0 2.7
Mmu.3514 STAT1 . . 2.7 2.8
Mmu.3791 FOXP3 . . 2.9 2.7
Mmu.13081 IRF-6 3.0 3.2 . .
XM_001084631 RAG1 11.1 30.1 . .
Co-stimulatory
Mmu.3359 CD80 . . . 2.1
Acute phase/anti-bacterial
Mmu.3013 CRP 12.1 36.3 . .
XM_001103896 MPO 8.8 20.5 . .
Mmu.1820 Lysozyme . . 3.7 4.4
Others
Mmu.11930 Serum amyloid P component 6.1 6.8 . .
Mmu.12026 Solute carrier fam. 11 2.4 2.3 . .
Spleen derived marginal zone B-cells were sorted as described in Materials and methods section (n¼3 healthy vs n¼3 infected). The different analytical methods comparing
the mean or median fold up- or down-regulation delivered similar results. PRR¼Pattern Recognition Receptors.
T. Demberg et al. / Virology 484 (2015) 323–333330
resulting from TLR stimulations (Johnson et al., 2009). Therefore a
CD40L signal could be provided by DC or related cells of the
monocyte/macrophage lineage present in the marginal zone Gordon
et al., 2014. In any case, the question regarding CD40L provided by
CD4 T cells is moot, as no decline in this cell population was observed
over the course of infection, at least in peripheral blood. Absolute CD4
T cell counts prior to challenge and 8 and 20 weeks post-challenge
were 834781, 821776, and 800784 for the vaccinated macaques
and 808792, 755778, and 8447129 for the control macaques,
respectively. We did not evaluate CD4 T cell counts in LN and spleen.
It has been well documented that skewing of B-cell memory
populations occurs following SIV/SHIV infection, and our data
conﬁrm this (Fig. 4B). The inhibitory molecules CD22 and BTLA
were expressed at lower levels in SHIV infection, CD22 signiﬁ-
cantly so (Fig. 3F). In contrast to the downregulation seen here,
upregulation of CD22 has been described as a feature of an
exhausted B-cell phenotype among different human B-cell popu-
lations (Moir and Fauci, 2009; Moir et al., 2008). The conﬂicting
results might represent species differences.
We observed changes in homing markers, noting a skewing
following SHIV infection, with signiﬁcantly lower expression of
CCR6 on splenic MZ B-cells obtained in the late chronic phase
(Fig. 7C). Trends towards increases in the expression of CXCR4
(Fig. 7D) and α4β7 (Fig. 7E) were also observed. CXCR4 is important
for shuttling between light and dark zones of germinal centers (Allen
et al., 2007; Victora and Mesin, 2014). However, whether MZ B-cells,
potentially laden with antigen post-infection increase trafﬁcking to
the light zone to present captured antigen to other B-cells or follicular
dendritic cells remains speculation at this point. The non-signiﬁcant
increases in α4β7 and CXCR4 expression (Fig. 7D and E) might also
suggest that some MZ B-cells having acquired an “activated” pheno-
type marked by Ki-67 and CD69 upregulation (Fig. 5C and D) are
prepared for homing to the mucosa (α4β7) or bone marrow (CXCR4).
Trends toward decreased BCL-2 and increased active Caspase
3 expression in splenic MZ B cells late in the chronic phase of SHIV
infection (Fig. 6A and B) were associated with increased CD69þ , Ki-
67þ , and IgMþ cells. CD69 is a common T-cell activation marker, but
its regulation differs in B-cells (Vazquez et al., 2009) where Toll-like
receptor as well as BCR engagement can increase its expression
(Minguet et al., 2008). While TLR stimulation leads to upregulation
of CD40 as well as CD69 (Jain et al., 2011; Kaminski et al., 2012), we
did not observe higher levels of CD40 on MZ B-cells in infected
animals (Fig. 6C and data not shown). However, CD40 already
exhibited high baseline expression levels (Table 2). Overall, our
ﬁndings here support the hypothesis that the marginal zone B-cells
are “lost” in part due to constant immune activation. Future work will
be needed to substantiate this hypothesis.
The PCR array data obtained from a limited number of animals
must be interpreted cautiously but raises interesting questions for
future exploration. Using a stringent 2-fold cut off, we observed
that many cytokines/chemokines that can be produced by B cells,
such as GM-CSF, IFN-b1, IL-10, IL-13, IL-1a, IL-2, IL-4 and IL-8
(Hamze et al., 2013; Pistoia, 1997) were downregulated (Table 3).
Whether MZ B-cells can produce and secrete all of the cytokine/
chemokines we detected by RNA needs further veriﬁcation. While
IL-10 secretion has been attributed to MZ B-cells, for example
(Buchta and Bishop, 2014; Shen et al., 2013), RNA (cDNA) detection
does not necessarily relate to translated protein as shown for IL-15
(Onu et al., 1997). The downregulation of complement component
C3, but upregulation of MBL2 might indicate skewing of the
complement system’s physiological roles beyond the scope of host
defense as discussed by Kolev et al. (2014). Whether MZ B cells
play a role in the complement mediated crosstalk between cell
effector systems warrants further research. The TNF-family death
receptor CD95 (FAS) was slightly elevated (1.6-fold) in chronic
infection although it did not reach the 2-fold cut-off. Thus we
cannot rule out that the loss of some MZ B-cells might be due to
FAS-FAS-L mediated apoptosis. On the other hand FAS has also
shown non-apoptotic activities such as cellular activation, prolif-
eration and maturation, as discussed elsewhere (Peter et al., 2007;
Strasser et al., 2009), and therefore may not have contributed to
MZ B cell loss. Expression of TLRs on Rhesus macaque B-cells has
not been described, but it might be similar to that of humans. TLRs
are expressed to varying degrees on human B-cell subsets (Buchta
and Bishop, 2014; Dorner et al., 2009). In mice, TLR3 seems to be
somewhat more broadly expressed on MZ B-cells (Buchta and
Bishop, 2014). However, the contributions of TLR signaling to the
development and function of human MZ B-cells have not been
elucidated (Weill et al., 2009). We observed a non-signiﬁcant
decline in the expression of TLR5 and also TLR3 on MZ B cells
from infected animals. This loss of TLR expression could be in line
with activation induced differentiation into another B-cell pheno-
type, as discussed above. Tonsilar memory B-cells in humans do
not express TLR3 and express reduced levels of TLR5 (Dorner et al.,
2009). However whether a MZ B-cell can differentiate into a B-cell
memory phenotype, for example, needs to be further investigated.
In summary we have conﬁrmed the MZ B cell phenotype
previously described for cynomolgus monkeys and extended the
phenotype of this B cell subpopulation to spleen and LN tissues of
rhesus macaques. In addition we show that SHIV affects MZ B-cells
early in chronic infection, and that these effects persist in late
chronic phase despite control of plasma viremia to low or
undetectable levels. Thus we extend the work of Peruchon et al.
(2009) who showed alteration in the MZ B cell population of
cynomolgus monkeys during the ﬁrst four weeks of SIV infection.
Effects of long-term SHIV infection shown here included changes
in frequency, activation, regulatory markers, antibody isotypes and
homing preferences. The changes observed suggest that the ability
of MZ B cells to fulﬁll their role as mediators of early adaptive
immune responses is hampered by virus infection. At this moment
it is unknown if the loss of MZ-B-cells is unique to SHIV infection
or is a more common occurrence in chronic viral infections.
Unpublished work by Stephen Waggoner and Stacey Cranert
(Cincinnati Children’s Hospital Medical Center; personal commu-
nication), shows that MZ B-cells are also lost in chronic LCMV
infection of mice. Further, both a loss and an increase of MZ B-cells
was reported following infection of mice with two different
species of Borrelia Malkiel et al., (2009). Thus the pathogen might
play an important role in the biology of MZ B-cells. Ex-vivo
stimulation experiments from sorted MZ B-cells are needed to
further elucidate the role and functions of this subset in the SHIV
and SIV Rhesus macaque models. Overall, loss or dysregulation of
MZ B-cells could impact antibody responses to the ongoing
infection, acquisition of opportunistic infections, as well as HIV
therapeutic vaccine approaches.
Materials and methods
Macaque samples
Animals were housed at Advanced BioScience Laboratories, Inc.
(ABL; Rockville, MD) or at the NCI Animal Facility (Bethesda, MD),
and maintained in accordance with the standards of the American
Association for Accreditation of Laboratory Animal Care and the
NIH Guide for the Care and Use of Laboratory Animals. Experi-
mental protocols were reviewed and approved by Institutional
Animal Care and Use Committees prior to initiation of studies.
Lymph node (LN) samples were obtained retrospectively from a
previously published pre-clinical rhesus macaque vaccine study
(Thomas et al., 2014) pre-vaccination (n¼24, 16 immunized and
8 controls) and at the initiation of the chronic phase of infection,
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8 weeks after intrarectal SHIVSF162P4 challenge (n¼18, 13 immu-
nized and 5 controls). At this time point, plasma viral loads
between immunized and control macaques were not different
(Fig. 1), so the LNs were grouped for further study. In addition,
spleens and PBMC were obtained from a random subset of animals
(n¼8) from that study at necropsy in late chronic phase (26 to 28
weeks post-infection) at which time viral loads were undetectable
in 6 of the 8 macaques (Fig. 1). Geometric mean viral loads for the
macaques studied at wk 8 post-infection and at necropsy were
9.0102 and 1.2102 RNA copies/ml plasma, respectively.
Spleens from 4 uninfected animals were used as controls.
Tissue preparation
PBMC were isolated by ﬁcoll paque (GE Healthcare) gradient
centrifugation, washed and remaining red blood cells were lysed
with ACK lysis buffer (Lonza). Splenocytes and LN cells were
isolated by cutting the spleen or LN open and carefully scraping
out the cells. The isolated cells were mixed with culture medium
and passed through a 70 μm cell strainer (BD biosciences). After
washing, red blood cells were lysed using ACK lysis buffer.
Following a subsequent wash in PBS the cells were counted and
used fresh for ﬂow cytometry staining. Remaining cells were
viably frozen and stored in liquid nitrogen until further use.
Flow cytometry
For cellular phenotyping 1–2106 cells/tube were used per stain-
ing. Antibody details are summarized in Table 1. In brief, following
25min surface staining, cells were washed in PBS, ﬁxed and permea-
bilized according to the manufacturer’s instructions using Fix and Perm
or a transcription buffer set for IRF-4 and BCL-6 (BD Bioscience, San
Jose, CA). After washing, intracellular staining was conducted according
to the respective buffer set instructions. After staining, cells were
washed, resuspended in PBS containing 2% Formaldehyde (Tusimis,
Rockville, MD), and acquired within 24 h on a custom 4-laser LSR II (BD
Bioscience). A minimum of 50000 live cells in the lymphocytic gate
were acquired in DIVA. Analysis was performed in FlowJo, and data
were exported into Excel and GraphPad Prism 6.
For the sorting of spleen cells from healthy and randomly chosen
SHIV-infected macaques, approximately 20106 viable cells were
stained per sample. Cells were thawed and washed in RPMI1640 with
L-glutamine and anti-bacterial anti-fungal solution (all from Invitro-
gen). The cells were counted and stained with viability dye aqua
followed by surface staining with CD2 PE, CD14 Qdot605, CD19 PeCy5,
CD21 PeCy7 and CD27 PerCP-eF710. Dead cells, CD2þ and CD14þ
cells were excluded, and MZ B-cells were sorted as CD19þ and
CD21bright on the highest purity setting using a 75-um nozzle on a
FACSAria II (BD Bioscience) or a MoFlo Astrios EQ (Beckman Coulter).
Rhesus macaque PCR array
RNA from sorted cells was extracted using the Qiagen RNeasy mini
kit. cDNA was generated after quantifying RNA yield and purity on a
Nanodrop photometer with the Qiagen QuantiTect reverse transcrip-
tion kit with genomic DNA elimination buffer. PCR array plates (RT2
Proﬁler PCR array no. 330231PAQQ-052ZA, Qiagen) were handled and
loaded according to the manufacturer’s instructions. For the PCR
reaction we used Invitrogen SYBR greenER PCR universal mix and an
ABI 7500 real-time PCR machine. Data were analyzed using SDS
software, exported into Excel and GraphPad Prism. Differences were
calculated with the ΔΔCt method and undetectable responses were
set to a Ct value of 35 (cut-off value for positive signal) to allow for
comparison and statistical analysis. An increase or decrease of 2-fold
was used as a cut-off criterion.
Statistical analysis
The comparisons between healthy controls (n¼4) and infected
animals (n¼8) over several classes of outcomes were assessed
using the exact Wilcoxon rank sum test. Changes from pre-
infection to week 8 post-infection in total B-cells, MZ B-cells and
the expression of Ki-67, CD22 and IgD were modeled using
repeated measures analysis of variance after logarithmic transfor-
mation of the raw data. Correlations of MZ B-cell and Ki-67
changes with viral loads were calculated by the Spearman method.
For the paired analyses of CD27 and CD38 MFIs in B-cell subsets,
the exact Wilcoxon signed rank test was used. Due to the
exploratory nature of this investigation, p values were not cor-
rected for multiple comparisons. Values o0.05 therefore indicate
noteworthy differences and were labeled as signiﬁcant, but some
conclusions involving simultaneous tests or values 40.01 are
tentative until conﬁrmed in independent studies. Informal con-
sideration was given to the internal consistency of potentially
correlated results and to the limited power of nonparametric
methods applied to data from the small numbers of available
animals in this study.
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